Kalvista Pharmaceuticals (NASDAQ:KALV) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research note issued to investors on Thursday.
According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. “
Several other analysts also recently weighed in on the stock. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Roth Capital assumed coverage on shares of Kalvista Pharmaceuticals in a report on Tuesday, July 10th. They issued a “buy” rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating and three have issued a buy rating to the company. Kalvista Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $22.00.
Kalvista Pharmaceuticals stock opened at $16.26 on Thursday. Kalvista Pharmaceuticals has a fifty-two week low of $6.65 and a fifty-two week high of $18.90. The company has a market capitalization of $215.98 million, a P/E ratio of -10.63 and a beta of 3.02.
Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative net margin of 132.38% and a negative return on equity of 54.93%. The company had revenue of $3.72 million during the quarter, compared to analyst estimates of $4.11 million. equities analysts expect that Kalvista Pharmaceuticals will post -0.93 earnings per share for the current fiscal year.
In related news, Director Albert Cha bought 1,058,824 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $18,000,008.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 38.40% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. Spark Investment Management LLC acquired a new position in shares of Kalvista Pharmaceuticals in the second quarter worth $108,000. BlackRock Inc. grew its stake in shares of Kalvista Pharmaceuticals by 203.8% in the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 10,871 shares in the last quarter. DRW Securities LLC grew its stake in shares of Kalvista Pharmaceuticals by 37.3% in the second quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after acquiring an additional 5,600 shares in the last quarter. Stanley Laman Group Ltd. grew its stake in shares of Kalvista Pharmaceuticals by 48.3% in the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after acquiring an additional 21,861 shares in the last quarter. Finally, Eventide Asset Management LLC grew its stake in shares of Kalvista Pharmaceuticals by 26.9% in the first quarter. Eventide Asset Management LLC now owns 900,000 shares of the specialty pharmaceutical company’s stock worth $8,532,000 after acquiring an additional 191,000 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Article: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.